Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
United Therapeutics Corp Market Cap
From what 17 stock analysts predict, the share price for United Therapeutics Corp (UTHR) might increase by 5.52% in the next year. This is based on a 12-month average estimation for UTHR. Price targets go from $221 to $600. The majority of stock analysts believe UTHR is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 17 Wall Street analysts have assignedUTHR 9 buy ratings, 6 hold ratings, and 2 sell ratings. This means that analysts expect United Therapeutics Corp to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on UTHR. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of UTHR.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Chris Shibutani Goldman Sachs | Neutral | $302 | Maintains | Nov 1, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $425 | Maintains | Oct 31, 2024 |
| Matthew Kaplan Ladenburg Thalmann | Buy | $344 | Maintains | Oct 31, 2024 |
| Jasper Hellweg Argus Research | Buy | $400 | Maintains | Oct 31, 2024 |
| Hartaj Singh Oppenheimer | Outperform | $600 | Maintains | Oct 31, 2024 |
| Joseph Thome TD Cowen | Buy | $400 | Maintains | Oct 21, 2024 |
| Eun Yang Jefferies | Buy | $432 | Maintains | Sep 23, 2024 |
| Hartaj Singh Oppenheimer | Outperform | $575 | Maintains | Aug 28, 2024 |
| Tiago Fauth Wells Fargo | Overweight | $380 | Maintains | Aug 20, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $400 | Reiterates | Aug 1, 2024 |
| Greg Harrison B of A Securities | Underperform | $280 | Maintains | Aug 1, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $400 | Maintains | Jul 25, 2024 |
| Joseph Thome TD Cowen | Buy | $350 | Maintains | Jul 11, 2024 |
| Terence Flynn Morgan Stanley | Equal-Weight | $321 | Downgrade | Jul 11, 2024 |
| Ashwani Verma UBS | Buy | $370 | Maintains | Jul 8, 2024 |
| Tiago Fauth Wells Fargo | Overweight | $350 | Maintains | Jun 12, 2024 |
| Jessica Fye JP Morgan | Overweight | $300 | Maintains | May 21, 2024 |
| Chris Shibutani Goldman Sachs | Neutral | $240 | Maintains | May 3, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $300 | Reiterates | May 2, 2024 |
| Hartaj Singh Oppenheimer | Outperform | $400 | Maintains | May 2, 2024 |
When did it IPO
1999
Staff Count
1,168
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.
Market Cap
$16.17B
In 2023, UTHR generated $2.33B in revenue, which was a increase of 20.20% from the previous year. This can be seen as a signal that UTHR's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 29 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - United Therapeutics (UTHR) reported earnings 30 days ago; investors should monitor upcoming developments and market reactions for future stock performance.
Why It Matters - Earnings reports can influence stock prices. Upcoming performance expectations, guidance, and market reaction to recent results will impact UTHR's valuation and investor sentiment.
Thu, 14 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - United Therapeutics' stock rose 300% since 2020, fueled by Tyvaso DPI sales. The company combats generic competition through litigation and innovation, focusing on market expansion and new treatments.
Why It Matters - United Therapeutics' stock surge reflects strong sales and strategic resilience against competition, signaling potential for continued growth through market expansion and innovative treatments.
Fri, 15 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - United Therapeutics leads in PAH treatments with Tyvaso as its main revenue source. Legal challenges, especially with Liquidia, pose risks to its IP and competitive stance.
Why It Matters - United Therapeutics' leadership in PAH treatments and innovation in organ transplantation are key growth drivers, but ongoing legal challenges could jeopardize its market position and revenue streams.
Fri, 15 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - United Therapeutics (UTHR) reported strong Q3 FY '24 earnings with significant YoY growth in Tyvaso, Orenitram, and Unituxin. Analysts project 40% earnings growth in the next 2-3 years.
Why It Matters - UTHR's strong earnings growth and competitive advantages signal potential for substantial returns, making it an attractive prospect for investment in the biotech sector.
Tue, 05 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Zacks Premium research service offers Zacks Style Scores, aiding all investor types—value, growth, or momentum—in identifying strong stocks.
Why It Matters - Zacks Style Scores can enhance stock selection for various investment strategies, potentially improving portfolio performance and attracting investor interest in the Zacks Premium service.
Tue, 05 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - United Therapeutics Corporation (Nasdaq: UTHR) will discuss company operations at the UBS Global Healthcare Conference on November 12, 2024, from 2:45 to 3:20 PM PST.
Why It Matters - The presentation by United Therapeutics' EVP at a prominent healthcare conference could influence investor sentiment, providing insights into operations and potential growth drivers.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
